Published : 01 Jun 2011
Today the Life Sciences research arm of a Japanese conglomerate has appointed Aagami as its Regulatory consulting advisors.
The Japanese company has developed novel diagnostic device for several oncology biomarkers. The device and technology has been approved in Japan for RUO and has been applied for clinical use as well. The company has been doing several research studies in collaboration with the US Universities and now would like to bring this product to the American market.
Aagami will devise their US entry strategy as well as consult them in obtaining necessary regulatory clearance.